P4HA2 activates mTOR via hydroxylation and targeting P4HA2-mTOR inhibits lung adenocarcinoma cell growth

Ersuo Jin,Shengjie Wang,Donglai Chen,Jia-Ping Wang,Yuanyuan Zeng,Runfeng Sun,Hong-Tao Zhang

DOI: https://doi.org/10.1038/s41388-024-03032-1

IF: 8.756

2024-04-24

Oncogene

Abstract:Mammalian target of rapamycin (mTOR) kinase functions as a central regulator of cell growth and metabolism, and its complexes mTORC1 and mTORC2 phosphorylate distinct substrates. Dysregulation of mTOR signaling is commonly implicated in human diseases, including cancer. Despite three decades of active research in mTOR, much remains to be determined. Here, we demonstrate that prolyl 4-hydroxylase alpha-2 (P4HA2) binds directly to mTOR and hydroxylates one highly conserved proline 2341 (P2341) within a kinase domain of mTOR, thereby activating mTOR kinase and downstream effector proteins (e.g. S6K and AKT). Moreover, the hydroxylation of P2341 strengthens mTOR stability and allows mTOR to accurately recognize its substrates such as S6K and AKT. The growth of lung adenocarcinoma cells overexpressing mTOR P2341A is significantly reduced when compared with that of cells overexpressing mTOR WT . Interestingly, in vivo cell growth assays show that targeting P4HA2-mTOR significantly suppresses lung adenocarcinoma cell growth. In summary, our study reveals an undiscovered hydroxylation-regulatory mechanism by which P4HA2 directly activates mTOR kinase, providing insights for therapeutically targeting mTOR kinase-driven cancers.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The problem this paper attempts to address is: exploring how prolyl 4-hydroxylase alpha-2 (P4HA2) activates mammalian target of rapamycin (mTOR) through hydroxylation and its impact on lung cancer cell growth. ### Main Research Content: 1. **Interaction between P4HA2 and mTOR**: - The study found that P4HA2 can directly bind to mTOR and hydroxylate the highly conserved proline 2341 (P2341) site in the kinase domain of mTOR. - This hydroxylation enhances the stability of mTOR, allowing it to more accurately recognize its substrates, such as S6K and AKT. 2. **Activation of the mTOR signaling pathway by P4HA2**: - Overexpression of P4HA2 can significantly increase the phosphorylation level of mTOR, thereby activating downstream effector proteins S6K and AKT. - Conversely, knockdown of P4HA2 leads to reduced mTOR expression, decreased phosphorylation levels of S6K and AKT, and inhibition of lung cancer cell growth. 3. **Impact of P4HA2 on mTOR stability and substrate recognition**: - Hydroxylation of P2341 is crucial for the stability of mTOR, as non-hydroxylated mTOR is prone to ubiquitin-mediated proteasomal degradation. - Hydroxylation at the P2341 site also affects mTOR's recognition of its substrates, such as S6K and AKT. 4. **P4HA2-mTOR as a potential target for lung cancer therapy**: - The study shows that the combined use of P4HA2 inhibitors (such as aspirin) and mTOR inhibitors (such as AZD-8055) can synergistically inhibit the growth of lung cancer cells. - This finding provides new insights for developing novel anti-cancer strategies targeting the mTOR signaling pathway. ### Conclusion: This study reveals a new mechanism by which P4HA2 directly activates mTOR through hydroxylation of the P2341 site. This discovery not only enhances the understanding of the regulatory mechanisms of the mTOR signaling pathway but also provides a theoretical basis for developing new anti-cancer drugs targeting the mTOR signaling pathway.

P4HA2 activates mTOR via hydroxylation and targeting P4HA2-mTOR inhibits lung adenocarcinoma cell growth

Activating transcription factor 4-dependent hsa-miR-663a transcription mediates mTORC1/p70S6K1 signaling underleucine deprivation

Activating transcription factor 4-dependent hsa-miR-663a transcription mediates mTORC1/p70S6K1 signaling underleucine deprivation.

Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma

Pyruvate Kinase M2 Activates Mtorc1 by Phosphorylating AKT1S1.

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth

Original Protein tyrosine phosphatase PTPN2 regulates TGF- signaling through Smad4 dephosphorylation

P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway

mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma

Mtor-Targeted Therapy: Differential Perturbation to Mitochondrial Membrane Potential and Permeability Transition Pore Plays a Role in Therapeutic Response.

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors

Phosphorylation of mammalian target of rapamycin in stage Ⅰ lung adenocarcinoma

Prohibitin Regulates Mtor Pathway Via Interaction with FKBP8

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma

Progress in mTOR study

Dual Inhibition of AKT ‐m TOR and AR Signaling by Targeting HDAC 3 in PTEN ‐ or SPOP ‐mutated Prostate Cancer

Abstract 4139: Prolyl 4-hydroxylase subunit alpha 1 acts as a novel target for lung adenocarcinoma brain metastasis